Peter Fischer
Peter gained his first degree and PhD in organic and medicinal chemistry under the supervision of Merlin EH Howden in Australia (Macquarie and Deakin Universities). After a short stint in a lectureship at Deakin University he entered into the biotechnology sector with a university drug discovery spin-out company in 1990.
Peter later moved to Norway, where he helped Nycomed (now part of GE Healthcare), a world-leading diagnostics company, establish a medicinal chemistry unit as part of a new therapeutics division. He then joined Sir David Lane at Cyclacel (then a Dundee-based start-up and now a public biopharmaceuticals company) to established chemistry and drug design capabilities, and subsequently led the discovery research activities at Cyclacel for almost eight years. Cancer drug candidates that were discovered there are currently under clinical investigation.
After a 15-year career in drug discovery and medicinal chemistry research and development in the pharmaceutical and biotechnology industry, Peter took the Chair in Medicinal Chemistry in the School of Pharmacy at the University of Nottingham in mid-2005. He directs the Centre for Biomolecular Sciences, which brings researchers together and fosters collaborative activities.
